|
|
Volumn 340, Issue , 2010, Pages
|
|
AstraZeneca pays $520m fine for off label marketing.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIBENZOTHIAZEPINE DERIVATIVE;
NEUROLEPTIC AGENT;
QUETIAPINE;
DRUG INDUSTRY;
ECONOMICS;
FINANCIAL MANAGEMENT;
HUMAN;
LEGAL ASPECT;
MENTAL DISEASE;
NOTE;
OFF LABEL DRUG USE;
ANTIPSYCHOTIC AGENTS;
DIBENZOTHIAZEPINES;
DRUG INDUSTRY;
HUMANS;
MARKETING OF HEALTH SERVICES;
MENTAL DISORDERS;
OFF-LABEL USE;
|
|
EID: 77952300437
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.c2380 Document Type: Note |
|
Times cited : (11)
|
|
References (0)
|
